A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

Integrating people-centered HIV care with primary health care is essential to improving access, equity and health outcomes, but doing so successfully requires coordinated policies, digital ...

While people living with HIV can lead virtually normal lives thanks to antiretroviral therapy (ART), HIV persists in a latent ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...

As HIV cases continue to rise in the Philippines, especially among the youth, a new global development may offer hope in ...

In the ongoing fight against HIV, scientists have taken a new step toward long-term control of the virus. Researchers have ...

Innovative, nontoxic molecules developed by a research team at the Institut national de la recherche scientifique (INRS) ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming infected with HIV. But big questions remain over the drug’s affordability.

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.

Researchers at the Department of Medicine, Huddinge, have presented new research on how some people with HIV can control the virus without treatment. The results show that gut bacteria and a ...

Scientists found a way to make the HIV virus visible, potentially laying the groundwork for ways to banish it from the body altogether.